Prevalence, Genotype Distribution and Persistence of Human Papillomavirus in Oral Mucosa of Women: A Six-Year Follow-Up Study

Rautava, Jaana; Willberg, Jaana; Louvanto, Karolina; Wideman, Lilli; Syrjänen, Kari; Grénman, Seija; Syrjänen, Stina

doi:10.1371/journal.pone.0042171

Cited by 62 publications

(98 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nine publications comprising 3762 cancer-free participants were identified and are presented in Table 1 [10][11][12][13][14][15][16][17][18]. Sample sizes ranged from 131 [11] to 1626 [12] participants.…”

Section: Resultsmentioning

confidence: 99%

“…The HPV Infection in Men (HIM) Study investigated men only from three countries (USA, Brazil and Mexico) [12,14]. The Finnish Family HPV Study analysed oral specimens from pregnant women, fathers-to-be and mothers [11,13,15,16]. Beachler et al included a US highrisk population (defined as 'HIV-uninfected people at risk of HIV infection') in their recent study [10].…”

Section: Resultsmentioning

confidence: 99%

“…HPV-16 type-specific clearance was less heterogeneous than overall HPV clearance and was lowest (43 %) in Finnish mothers [13] and highest (83 %) in two separate studies from the USA (the HIM Study and the high-risk population) [10,12]. Time to clearance of HPV-16 took 7 months in the HIM Study [12] and around 20 months for participants in three publications from the Finnish Family HPV Study [11,13,15]. Oral HPV clearance (as percentage cleared) was reported in three of the studies and time to clearance in two (Table 3).…”

Section: Oral Hpv Clearancementioning

confidence: 96%

“…Clearance for any oral HPV infection spanned from 0 % among pregnant women in the Finnish study [16] to 80 % in the US high-risk population [10], and time to clearance of any HPV type ranged from 6 to 18 months [11,15]. HPV-16 type-specific clearance was less heterogeneous than overall HPV clearance and was lowest (43 %) in Finnish mothers [13] and highest (83 %) in two separate studies from the USA (the HIM Study and the high-risk population) [10,12].…”

Section: Oral Hpv Clearancementioning

confidence: 99%

See 3 more Smart Citations

Oral human papillomavirus infection incidence and clearance: a systematic review of the literature

Wood

Bain

Smith

et al. 2017

Journal of General Virology

View full text Add to dashboard Cite

Subclinical oral human papillomavirus (HPV) infection that persists for decades is likely to precede an HPV-driven squamous cell carcinoma of the head and neck, but little is known about the natural history of oral HPV. We systematically reviewed and abstracted data from nine manuscripts that examined human immunodeficiency virusnegative and cancer-free subjects for oral HPV DNA to determine the pooled baseline prevalence and incidence of newly acquired oral HPV infections, and specifically for HPV-16. We also documented the clearance rate and the median time to clearance, where data existed. Of 3762 individuals, 7.5 % had an oral infection with any HPV type (1.6 % for HPV-16). Meta-regression analysis estimated the 12-month cumulative incidence to be 4.8 % (95 % confidence interval 3.2-7.3 %). The overall oral HPV clearance was reported to be 0-80 % between studies, and the median time to clearance from 6.5 to 18 months. Oral HPV-16 clearance was 43-83 %, and median time to clearance for HPV-16 was 7-22 months. Oral HPV prevalence, incidence and clearance vary considerably between published studies from different geographical regions. Further research is required to identify predictors of persistent oral HPV infection. Measurable baseline prevalence was observed in all studies, as well as non-trivial incidence of newly acquired oral HPV infections and incomplete clearance.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Oral Hpv Clearancementioning

confidence: 96%

Section: Oral Hpv Clearancementioning

confidence: 99%

See 2 more Smart Citations

Oral human papillomavirus infection incidence and clearance: a systematic review of the literature

Wood

Bain

Smith

et al. 2017

Journal of General Virology

View full text Add to dashboard Cite

show abstract

“…The mucosal HPV types are categorized as low-risk and high-risk types based on their oncogenic potential (1,2). The most common high-risk types are the HPV-16 and HPV-18, respectively, associated with pre-cancers and cancers in various anogenital sites (e.g., cervix, vulva, vagina, and anus) (3)(4)(5)(6). The studies showed that HPV-specific T-cell responses induced by vaccines play an effective role in tumor regression (7)(8)(9)(10).…”

Section: Introductionmentioning

confidence: 99%

Protein vaccination with HPV16 E7/Pep‐1 nanoparticles elicits a protective T‐helper cell‐mediated immune response

et al. 2016

View full text Add to dashboard Cite

Two human papillomavirus (HPV) viral oncoproteins, E6 and E7 represent ideal targets for development of a therapeutic HPV vaccine. It is important to reduce the rate of HPVassociated malignancies through improvement of vaccine modalities. In this study, we used a short amphipathic peptide carrier, Pep-1, for delivery of the full-length HPV16 E7 protein into mammalian cells and evaluated immune responses and protective effects of different formulations in C57BL/6 tumor mice model. Our results showed that the complexes of E7/ Pep-1 protein form stable nanoparticles through noncovalent binding with an average size of 120 to 250 nm. The efficient delivery of E7 protein by Pep-1 at molar ratio of 1:20 was detected in HEK-293T cell line for 1 h and 3 h posttransfection. Immunization with E7/Pep-1 nanoparticles at a ratio of 1:20 induced a higher Th1 cellular immune response with the predominant IgG2a and IFN-c levels than those induced by E7 protein in a murine tumor model. These data suggest that Pep-1 peptide would indicate promising applications for improvement of HPV therapeutic vaccines. V C 2016 IUBMB Life, 68(6): [459][460][461][462][463][464][465][466][467] 2016

show abstract

Outcomes After Human Papillomavirus Vaccination in Patients With Recurrent Respiratory Papillomatosis

Smahelova

Hamšíková

Ludvı́ková

et al. 2022

JAMA Otolaryngol Head Neck Surg

View full text Add to dashboard Cite

IMPORTANCE Recurrent respiratory papillomatosis (RRP) is a rare benign chronic disease of the larynx etiologically linked with the infection of low-risk human papillomavirus (HPV). Combination of surgical and immunomodulatory therapy has limited success. Possible use of prophylactic HPV vaccine that includes HPV-6 and HPV-11 antigens has been studied. OBJECTIVE To evaluate if the HPV vaccination is associated with a lower number of recurrences requiring surgical intervention in patients with new and recurrent RRP. DESIGN, SETTING, AND PARTICIPANTSThis was a non-placebo-controlled intervention study. Enrollment data were collected from October 2011 to August 2013. The patients were followed up at 1 month, 12 months, and 5 years after the third dose of the vaccine and clinically monitored until December 31, 2018. Data were analyzed from 2019 to 2021. Altogether, 50 adults with active RRP were enrolled and followed up in referral centers. For the final outcome, follow-up data for 42 patients were available. Eight patients who did not fulfill the protocol were excluded.INTERVENTIONS All patients received HPV vaccine as an adjuvant treatment and were clinically followed up. When RRP progression or a significant recurrent lesion was detected, surgical removal via direct laryngoscopy was indicated. No adjuvant therapy with antiviral or biological agents was used. MAIN OUTCOMES AND MEASURESThis study compared the prevaccination and postvaccination positivity for HPV-specific antibodies. The main outcome was the difference in the frequency of RRP recurrences in the prevaccination and postvaccination period.RESULTS A total of 50 patients with RRP were enrolled (median [SD] age, 41.5 [12.3] years [range,; 39 [78%] men and 11 [22%] women). After HPV vaccination, patients with previously no HPV-specific antibodies showed seroconversion, and all patients developed 100-fold higher levels of HPV vaccine type-specific antibodies compared with the prevaccination period. In patients with recurrent RRP, decreased frequency of recurrences requiring surgical treatment was present after vaccination (from 0.85 to 0.36 recurrences/y). No difference in postvaccination recurrences was found between patients with newly diagnosed and recurrent RRP. CONCLUSIONS AND RELEVANCEIn this nonrandomized clinical trial, the frequency of RRP recurrences was significantly lower after HPV vaccination, and patients with RRP thus had a reduced burden of disease. Because no difference was detected in the frequency of recurrent postvaccination lesions in patients with new and recurrent disease, it appears that both groups showed equal benefit following HPV vaccination. These findings suggest that the earlier that patients with RRP receive HPV vaccine, the sooner they may show reduced burden of disease.

show abstract

Prevalence, Genotype Distribution and Persistence of Human Papillomavirus in Oral Mucosa of Women: A Six-Year Follow-Up Study

Cited by 62 publications

References 25 publications

Oral human papillomavirus infection incidence and clearance: a systematic review of the literature

Oral human papillomavirus infection incidence and clearance: a systematic review of the literature

Protein vaccination with HPV16 E7/Pep‐1 nanoparticles elicits a protective T‐helper cell‐mediated immune response

Outcomes After Human Papillomavirus Vaccination in Patients With Recurrent Respiratory Papillomatosis

Contact Info

Product

Resources

About